STOCK TITAN

Bristol-Myers Squibb Co - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

Rhea-AI Summary

Exelixis has expanded its collaboration with Bristol-Myers Squibb to include a fixed-dose combination of nivolumab and relatlimab in the ongoing phase 1b STELLAR-002 clinical trial. This trial is evaluating XL092, Exelixis' next-generation oral tyrosine kinase inhibitor (TKI), combined with immune checkpoint inhibitors for advanced solid tumors. The study aims to determine the optimal dosing regimen across various combinations, enhancing treatment options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
-
Rhea-AI Summary

Bristol Myers Squibb (BMY) has received European Commission approval for Opdualag, a first-in-class combination treatment of nivolumab and relatlimab, for advanced melanoma in patients aged 12 and older with PD-L1 expression < 1%. This breakthrough comes from the RELATIVITY-047 trial, which showed Opdualag more than doubled median progression-free survival (PFS) to 6.7 months compared to 3.0 months for nivolumab alone. No new safety concerns were identified. This approval marks a significant advancement in melanoma treatment options within the EU, expanding patient access across member states.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) announced that the Phase 3 CheckMate -76K trial for Opdivo (nivolumab) in stage IIB/C melanoma has met its primary endpoint with a significant improvement in recurrence-free survival at a pre-specified interim analysis. The trial showed no new safety signals. Approximately one-third of stage IIB and half of stage IIC melanoma patients may experience recurrence within five years post-surgery. Opdivo's results offer potential advancements in cancer treatment, targeting earlier disease stages to improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
none
News
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) has announced a quarterly dividend of $0.54 per share, payable on November 1, 2022, to stockholders of record by October 7, 2022. Additionally, a dividend of $0.50 per share on its convertible preferred stock will be paid on December 1, 2022, to stockholders on record by November 8, 2022. This decision reflects the company's commitment to returning value to its shareholders while supporting its mission to develop innovative medicines.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.86%
Tags
dividends
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE:BMY) announced positive two-year results from the POETYK PSO long-term extension trial for Sotyktu™ (deucravacitinib), showing maintained efficacy in treating moderate-to-severe plaque psoriasis. Response rates at 112 weeks were 82.4% for PASI 75 and 55.2% for PASI 90. The data were presented at the 2022 European Academy of Dermatology and Venereology Congress, underscoring the company's commitment to dermatology research. These findings support Sotyktu’s role as a promising oral therapy for patients with psoriasis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb's Sotyktu™ (deucravacitinib) has received FDA approval as the first oral, selective TYK2 inhibitor for adults with moderate-to-severe plaque psoriasis, marking a significant innovation in treatment options after nearly a decade. The approval follows successful Phase 3 POETYK PSO clinical trials, which showed Sotyktu's superior efficacy over placebo and Otezla® in achieving skin clearance. This breakthrough therapy is anticipated to set a new standard of care and will be available to patients starting September 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) is launching its annual Coast 2 Coast 4 Cancer ride, starting from Cannon Beach, Oregon and ending in Long Branch, New Jersey on October 3. Over 126 employees will participate to raise awareness and funding for the V Foundation for Cancer Research. The event has raised over $9.83 million since its inception in 2014, with a target of surpassing $1 million this year. Participants include cancer survivors and those riding in memory of loved ones, with Bristol Myers Squibb matching donations up to $500,000.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE:BMY) will announce its third-quarter 2022 financial results on October 26, 2022, during a conference call at 8:00 a.m. ET. The call will include a review of the financial results and a Q&A session with investors and analysts. A live webcast is available for the public at investor.bms.com. The call can also be accessed via phone by dialing 877-502-9276 in the U.S. Participants can replay the call starting 11:30 a.m. ET on the same day until November 9, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
conferences
-
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 a.m. ET in New York City. Executive Vice Presidents Chris Boerner, Ph.D., and Samit Hirawat, M.D., will address questions regarding the company's operations. A live webcast will be accessible at investor.bms.com, with an archived version available later that day.

Bristol Myers Squibb focuses on developing innovative medicines for serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.06%
Tags
conferences
Rhea-AI Summary

Bristol Myers Squibb (NYSE: BMY) presented significant research at the ESMO Congress 2022, underscoring the impact of Opdivo (nivolumab) in treating various cancers. Key findings include positive long-term survival data from Opdivo-based therapies and supportive evidence for its combination with other agents in advanced melanoma, non-small cell lung cancer, and urothelial carcinoma. Over 90 studies will be showcased, emphasizing the ongoing commitment to cancer treatment and personalized medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Bristol-Myers Squibb Co (BMY)?

The current stock price of Bristol-Myers Squibb Co (BMY) is $57.38 as of February 26, 2025.

What is the market cap of Bristol-Myers Squibb Co (BMY)?

The market cap of Bristol-Myers Squibb Co (BMY) is approximately 118.1B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Bristol-Myers Squibb Co

Nasdaq:BMY

BMY Rankings

BMY Stock Data

118.13B
2.02B
0.12%
78.52%
1.36%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON